RE: VKTX at twitter,
Guys at Twitter are just BS (repeating each other), so "tackle" their imagination is just waste of time.
Than, ...idea to have "dose range options" in pocket is OK, but...first they need to clear long term tox data from primate, than extrapolate to current PK/PD data,....than calculate best exposure efficacy range.....and all that before they have meeting with FDA. Long way to go.
I am today more optimistic on 2809 than yesterday (they cleared near term liver tox problems), they have comparable efficacy to 3196 (actually I do believe that they will surpass 3196 efficacy, IF they can hold to current dose...that I already mentioned early...), it is a comfort that many bios do not have. Still, management was short on informing investor about what was actually going on with P2 trial? That is discomfort. And, discomfort has two times weight of the comfort...and so on....
Cheers, Miljenko |
